

Form PTO-1449

Atty. Docket:
452005-13Serial No.:
09/935,322

INFORMATION DISCLOSURE STATEMENT

NOV 25 2002

Applicant: Dang et al.

Filing Date: August 22, 2001

Group: 1616

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Sub-Class	Filing Date
KA	6,462,094	10/8/02	Dang et al.	514	849	8/22/01
	6,417,206 B1	7/9/02	Leflein et al.	514	352	1/26/01
	6,306,904 B1	10/23/01	Gordziel	514	530	7/25/00
	6,287,597 B1	9/11/01	Gordziel	424	464	3/12/99
	6,037,358	3/14/00	Gordziel	514	357	3/24/99
	5,807,579	9/15/98	Vilkov et al.	424	469	11/14/96
	5,663,415	9/2/97	Chopdekar et al.	560	68	6/28/96
	5,599,846	2/4/97	Chopdekar et al.	514	653	6/28/96
	5,164,398	11/17/92	Sims et al.	514	282	4/1/91
	4,601,714	7/22/86	Burnhill	604	286	3/7/84

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Sub-Class	Translation
KA	64,007,786 (abstract)	8-31-93	JP	—	—	
KA	06287144	01-02-95	JP	—	—	
KA	39007786	05-18-64	JP	—	—	YES

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

KA	Weiler et al., "Randomized, double blind, parallel groups, placebo-controlled study of efficacy and safety of Rynatan in the treatment of allergic rhinitis using an acute model," Annals of Allergy, vol. 64(1): 63-67
	Goldberg et al., "Evaluation of a Prolonged Action Oral Antihistaminic Preparation as Treatment for Allergic Disorders," Clinical Medicine, vol. 72(9): 1475-1479.
	TRIPLE TANNATE, Drug Launches (doc. #: 0182701) 5/99
	TUSSI-12, Drug Launches (doc. #: 0179128) 3/99
KA	TUSSI-12, Drug Launches (doc. #: 0176901) 12/98

Examiner:

Date Considered:

1/27/03

EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED
PATENT & TRADEMARK OFFICE

TECH CENTER 1600/2900
NOV 29 2002

RECEIVED
NOV 29 2002

TECH CENTER 1600/2900
NOV 29 2002

RECEIVED
NOV 29 2002

Form RP 1449
INFORMATION DISCLOSURE STATEMENTAtty. Docket:
452005-13Serial No.:
09/935,322

Applicant: Dang et al.

Filing Date: August 22, 2001

Group: 1616

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Sub-Class	Filing Date
JA	B1 4552,899	10/20/92	Sunshine et al.	514	568	4/9/84
	4,552,899	11/12/85	Sunshine et al.	514	568	4/9/84
	3,061,517	10/30/62	Walter	167	65	2/16/62
	3,018,221	1/23/62	Millar et al.	167	65	3/28/58
	2,798,024	7/2/57	Zappas et al.	167	82	6/2/54
	2,757,124	7/31/56	Wolff	167	82	3/8/52
	20010011104	8/2/01	Gordziel	514	653	12/11/98

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

JA	R-TANNATE, Drug Launches (doc. #: 0172212) 8/98
	TRIPLE TANNATE, Drug Launches (doc. #: 0163340). 1/98
	ATROHIST, Drug Launches (doc. #: 0154800). 5/97
	GELHIST, Drug Launches (doc. #: 015445). 5/97
	PHENATAN, Drug Launches (doc. #: 0149758) 1/97
	TRIOTANN, Drug Launches (doc. #: 0136052) 12/95
	TRI-TANNATE, Drug Launches (doc. #: 0129566) 6/95
	RICOBIN-D, Drug Launches (doc. #: 0129564) 6/95
	RICOBID, Drug Launches (doc. #: 0129563) 6/95
	QUAD-TUSS TANNATE, Drug Launches (doc. #: 0127440) 4/95
	TRI-TANNATE, Drug Launches (doc. #: 0179121) 3/99
	TRITAN, Drug Launches (doc. #: 0144945) 9/96
	TRI-NATAN, Drug Launches (doc. #: 0110372) 11/93
	R-TANNATE, Drug Launches (doc. #: 0110158) 11/93
JA	TRIN TUSS, Drug Launches (doc. #: 0049139) 3/93

Examiner:

Date Considered:

EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

